Starting this year and for the next four years, NADFC will go into partnership with Japan International Cooperation Agency (JICA) to ensure the safety of pharmaceutical products and food products in Indonesia; one of them is concerning the activities of Pharmacovigilance. A series of activities to promote this project have been carried out. From 23 to 30 September, 2013 JICA once again gave supports to “Strengthening of Pharmacovigilance Activities” as the follow-up activities of the joint project. Several staff members of NADFC and Provincial office of NADFC were sent to Japan to learn and to observe directly the system of Japanese Pharmacovigilance and to get the positive points to be implemented in Indonesia. Those activities were participated by Director of Distribution Control of Therapeutic Product and Household Medical Supplies, the Chairman of Provincial Office of NADFC in Medan, the Chairman of Provincial Office of NADFC in Padang, the Chairman of Provincial Office of NADFC in Menado, Section Head of Surveillance of Therapeutic Product and Household Medical Supplies, and also staff members of Directorate of Distribution Control of Therapeutic Product and Household Medical Supplies and staff members of Directorate of Drug and Biological Product Evaluation.
The agenda of the activities were scheduled comprehensively; there were visitations, learning and discussions by visiting several locations, among others: Ministry of Health, Labor and Welfare, Pharmaceuticals and Medical Device Agency (PMDA), JICA Headquarters, National Center for Child Health and Development, Eisai Japan, and Towa Pharmaceutical Co., Ltd.. Besides developing effective pharmacovigilance for Indonesia, the activities are also targeted on development of Risk Management Plan (RMP) guidelines which is planned to be finalized in 2017, and development of regional center in Provincial Office of NADFC in order to strengthen pharmacovigilance in the entire territory of Indonesia so that consistency insecurity of distributed drugs and patient safety can be achieved.
The important points that can be implemented from the activities above are to empower and to raise the awareness of all parties concerning the supervision of pharmacovigilance by introducing pharmacovigilance to university students, and asking for supports from professional associations and pharmaceutical industry. These supports are certainly needed to put pharmacovigilance into effect in Indonesia. (sc).